Dr. Reddy’s Laboratories announced that certain batches of semaglutide are out of specification due to an issue with the active pharmaceutical ingredient (API). The company is investigating the root cause and implementing corrective actions. Commercial supplies of the product will be delayed as a result, although patient safety and regulatory filings remain unaffected. A conference call will be held on July 9, 2026, to discuss the matter.
Product Quality Issue Identified
Dr. Reddy’s Laboratories has informed stakeholders of an issue concerning certain batches of its semaglutide product. These batches have been found to be out of specification. The identified problem is linked to the active pharmaceutical ingredient (API) used in the manufacturing process.
Investigation and Corrective Actions Underway
The company has initiated a thorough investigation to determine the root cause of this deviation. Concurrently, Dr. Reddy’s is actively implementing appropriate measures to address the situation and ensure product quality. The focus remains on resolving the issue to maintain the high standards expected for this important metabolic therapy.
Impact on Commercial Supplies and Patient Safety
As a consequence of this issue, commercial supplies of the affected semaglutide product will experience delays for a certain period. Dr. Reddy’s emphasizes that there is no impact on patient safety, nor is there any adverse effect on the product’s existing global regulatory filings. The company reaffirms its commitment to ensuring reliable global supplies.
Conference Call Details
To provide further details and address queries, the management of Dr. Reddy’s Laboratories will host a conference call. The call is scheduled for Thursday, July 9, 2026, from 16:30 to 17:00 IST (07:00 – 07:30 ET). Interested participants can pre-register via the provided link: https://drreddys.zoom.us/webinar/register/WN_48dgDpglTjy7yDxzjxO_yQ. The audio link and transcript will be made available on the company’s website.
Source: BSE
